58 results about "Inosine" patented technology

The invention belongs to the field of in-vitro diagnostic reagents, and particularly relates to application of a reagent for detecting biomarkers in serum in preparation of a cerebral arterial thrombosis diagnostic kit. The invention determines that the concentrations of lactic acid, isoleucine, fumaric acid, ketoglutaric acid, hypoxanthine, tyrosine, histidine and inosine in serum of a cerebral arterial thrombosis (IS) patient are significantly related to major atherosclerosis (LAA) and minor artery occlusion (SAO), so that the concentrations of the biomarkers can be used as a basis for diagnosing IS and distinguishing LAA and SAO.

Provided herein is a eukaryotic cell expressing an exogenously introduced inosine 5'-monophosphate dehydrogenase (IMPDH) that is resistant to a purine biosynthesis inhibitor, uses thereof for producing therapeutic agents and treating a disease or disorder, as well as pharmaceutical compositions and methods of making thereof.

Provided herein is an antisense oligonucleotide (ASO) for use in the prevention or treatment of a disease or a condition associated with ApoB in a subject, wherein the ASO effects site- directed adenosine-to-inosine (A-to-l) editing of a target adenosine in a target RNA sequence derived from a sequence of an endogenous ApoB gene.

An agent is for inhibiting glucose uptake into red blood cells and a blood collection tube suppresses glucose concentration decrease. The agent for inhibiting glucose uptake into red blood cells includes inosine as an active ingredient. The inhibition agent can be used for suppressing a decrease in glucose concentration of whole blood collected in a blood collection tube. The blood collection tube includes inosine in an internal space. The blood collection tube can be used to measure glucose concentration in blood. The blood collection tube can further include a glycolysis inhibitor.

This disclosure provides methods for treating neurodegenerative diseases and restoring neuronal synaptic function by administering adenosine-to-inosine editing modifiers.

The invention discloses a preparation method of 1, 7-dimethylxanthine, which adopts inosine as a starting material, and the developed catalyst porphyrin-loaded xanthine oxidase and nano metal oxide can be recycled for multiple times, thereby greatly lowering the production cost. More importantly, safety accidents occur frequently in recent years, a route design strategy for avoiding dangerous reactions becomes more and more important, and the route avoids the use of a diazotization dangerous process, so that the production safety risk is greatly reduced.

This invention discloses *Pediococcus lactis* TC-4, which simultaneously degrades nucleosides, purines, and uric acid, and its applications. *Pediococcus lactis* ( Pediococcus acidilactici This invention relates to *Pediococcus lactis* TC-4, with accession number GDMCC No: 67936. *Pediococcus lactis* TC-4 of this invention can efficiently degrade three nucleosides (guanosine, adenosine, and inosine), three purines (guanine, xanthine, and hypoxanthine), and uric acid in vitro. *Pediococcus lactis* TC-4 of this invention can effectively reduce serum uric acid levels in broiler chickens, alleviating and treating hyperuricemia. Compared with traditional chemical drugs for treating hyperuricemia and / or gout, this invention has no toxic side effects on the ecological environment, no residue risk, and is green and safe. This invention has been confirmed at multiple levels, including genetic and animal studies, to have no potential harm to humans, demonstrating its advantages of safety and high efficiency.

Provided are methods of manufacturing cells. The methods comprise expanding cells in the presence of inosine, and harvesting the cells after expansion. In certain embodiments, the cells are genetically modified. For example, the cells may be genetically modified to express an engineered receptor, non-limiting examples of which are chimeric antigen receptors (CARs), engineered T cell receptors (TCRs), and the like. According to some embodiments, the cells are immune cells, e.g., T cells or natural killer cells. Also provided are populations of cells manufactured according to the methods of the present disclosure. Also provided are methods comprising administering an effective amount of a population of cells manufactured according to the methods of the present disclosure to a subject in need thereof. In certain embodiments, the subject has cancer, and the cells express an engineered receptor that binds to a tumor antigen on the surface of cells of the cancer.

This invention relates to the field of probiotics technology, specifically to a Bifidobacterium adolescentis BN18 and its postbiotics for lowering uric acid and improving gout symptoms, and their applications. The Bifidobacterium adolescentis BN18 can promote the degradation of inosine and guanosine, thereby reducing uric acid levels in the blood. The postbiotics for Bifidobacterium adolescentis BN18 are made from carefully selected raw materials such as carrots, winter melon, blueberries, apples, lemons, and fructooligosaccharides as the core components of the composition. Through deep fermentation with BN18, the resulting postbiotics not only reduce the activity of xanthine oxidase and lower uric acid levels in the blood, thus promoting uric acid reduction, but also significantly enhance their antioxidant properties, reducing inflammatory responses, lowering inflammation levels, alleviating joint pain, and improving gout symptoms.

The present application relates to the field of bioengineering, and particularly relates to a protein mutant capable of improving the nucleoside yield of a strain and application thereof. The present application performs point mutation on adenine deaminase and pyrimidine nucleotide transport protein, which can effectively accumulate the inosine, adenosine and other nucleoside related products produced by the strain, does not affect the growth of the bacterial body, has wider practicality, and is conducive to reducing the cost of industrial production of nucleosides.

Provided is an immunogenic composition for use in raising immunity against the agent of Lyme disease. The composition is based on variants of CspZ and comprises a polypeptide of SEQ ID NO: 1, except that (a) the amino acid whose position corresponds to amino acid 188 of SEQ ID NO: 1 is any amino acid other than tyrosine; and the amino acid whose position corresponds to amino acid 192 of SEQ ID NO: 1 is any amino acid other than tyrosine; and (b) one or both of the amino acids acid whose position corresponds to amino acid 164 of SEQ ID NO: 1 may be an amino acid other than inosine and an amino acid whose position corresponds to amino acid 168 of SEQ ID NO: 1 may be an amino acid other than cysteine. Also provided is a polynucleotide encoding any of the foregoing polypeptides and a method of vaccinating against Lyme disease comprising administering the polypeptide or RNA encoding the polypeptide to a subject.

This invention discloses the application of inosine in the preparation of drugs that promote testosterone secretion, belonging to the field of biomedical technology. The effective active ingredient of the above-mentioned drugs is only inosine or its pharmaceutically acceptable salts. The dosage forms of the above-mentioned drugs are tablets, capsules, oral liquids, lozenges, granules, powders, pills, powders, ointments, elixirs, suspensions, powders, or injections. The routes of administration of the above-mentioned drugs are oral, transdermal, intramuscular, subcutaneous, or intravenous injection. Since inosine exists under physiological conditions and can be metabolized by intestinal microorganisms, reasonable supplementation of inosine is a safer and more effective method for restoring testosterone. Inosine helps maintain the homeostasis of the intestinal flora, and the experimental results of this invention further show that inosine can restore the damaged intestinal barrier, thus making it safer. Moreover, this invention does not directly supplement exogenous testosterone, therefore it is less likely to induce spermatogenesis disorders or promote prostatic hyperplasia.

The invention relates to the technical field of biologic detection of metabolomics, in particular to an OSAHS metabolism marker, a diagnosis model and application of the OSAHS metabolism marker and the diagnosis model. The metabolic marker comprises a red blood cell metabolite and / or a plasma metabolite; erythrocyte metabolites comprise L-aspartic acid, D-ribose-5-diphosphoric acid, cadaverine, 12, 13-epoxy octadecenoic acid, L-arginine, N-acetylmethionine, 5-hydroxyeicosatetraenoic acid, 13-oxo-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 10-tetrahydroxy-9Z, the component A is one or more of 11E-octadecadienoic acid, inosine monophosphate, nicotinamide, alpha-lactose, sphingosine, hydroxy octadecadienoyl or glyceraldehyde-3-phosphoric acid; the plasma metabolite is prepared from one or more of fumaric acid, cadaverine, L-aspartic acid, malic acid, sphingosine-1-phosphoric acid, L-arginine, cysteine-S-sulfate, thiosulfate, gamma-glutamyl alanine, galacturonic acid or vitamin B2.

The present disclosure provides, for instance, a method of detecting and quantifying RNA modifications. The RNA modification may be, for example, m6A, m6Am, m1A, hm5C, m5C, Ψ, or inosine. The method can comprise contacting the RNA with an antibody that binds the modification, and using a bar code approach to quantify the amount of RNA.

The invention relates to the field of microorganisms, in particular to a plant lactobacillus and application thereof. The invention provides lactobacillus plantarum, and the preservation number of the lactobacillus plantarum is GDMCC 66229. The lactobacillus plantarum has the advantages that the preservation number is CGMCC 66229, and the preservation number is CGMCC 66229; the lactobacillus plantarum SCUT732 provided by the invention has excellent acid resistance and bile salt resistance, has good beta-glucosidase activity, and has excellent capability of degrading uric acid precursor inosine and guanosine.

This invention provides a kit for the simultaneous detection of nine flavor nucleotides in livestock and poultry products. The flavor nucleotides are cytidine monophosphate, uridine monophosphate, guanylic acid, inosine monophosphate, adenosine monophosphate, hypoxanthine, inosine, adenosine diphosphate, and adenosine triphosphate. The kit includes: a high-concentration extraction reagent, a standard curve solution, a high-concentration phosphate buffer solution, pH adjustment solution A, and pH adjustment solution B. The high-concentration extraction reagent is perchloric acid; the standard curve solution is a mixed solution of the nine flavor nucleotides; the high-concentration phosphate buffer solution is a solution of potassium dihydrogen phosphate and dipotassium hydrogen phosphate; pH adjustment solution A is sodium hydroxide; and pH adjustment solution B is phosphate. This invention also provides a method for the simultaneous detection of the nine flavor nucleotides using the above kit. This invention enables the simultaneous determination of the content of nine flavor nucleotides in livestock and poultry products. The method is simple, rapid, accurate, and sensitive, and can be used for batch determination, showing good prospects for practical application.

This invention belongs to the field of biotechnology and relates to a strain of *Weizmannii coagulans* NJ01 for the biodegradation of inosine and guanosine, which can produce enzymes that catalyze the degradation of inosine and guanosine. This invention also relates to a preparation of *Weizmannii coagulans* NJ01 for degrading inosine and guanosine, containing bacterial cells and / or crude enzymes of the aforementioned *Weizmannii coagulans* NJ01 strain. Research results show that the *Weizmannii coagulans* NJ01 strain and its produced enzymes provided by this invention are safe for human use and can efficiently biodegrade inosine and guanosine, demonstrating significant value and application prospects in the removal of inosine and guanosine for the prevention and treatment of hyperuricemia, gout, and related complications in humans.

The application discloses a kind of pharmaceutical composition, and the pharmaceutical active ingredient of its drug includes desoximycin and meropenem.The composition can synergistically and efficiently inhibit klebsiella pneumoniae, especially KPC-2 positive carbapenem-resistant klebsiella pneumoniae and NDM-5 positive carbapenem-resistant klebsiella pneumoniae, with application prospect.

The present invention addresses the problem of providing: a composition that increases the amount of intracellular ATP and the amount of intracellular NAD; and a composition that improves motor performance. More specifically, the present invention provides a composition for increasing the amounts of intracellular adenosine triphosphate (ATP) and intracellular nicotinamide adenine dinucleotide (NAD), the composition being obtained by combining (a) and (b): (a) an NAD precursor or a pharmaceutically acceptable salt thereof; and (b) one or more substances selected from the group consisting of uridine and uridine precursors, or one or more pharmaceutically acceptable salts thereof, and / or one or more substances selected from the group consisting of inosine and inosine precursors, or one or more pharmaceutically acceptable salts thereof.　Furthermore, the present invention provides a composition for enhancing muscle strength, the composition being characterized by inclluding a combination of (c) and (d): (c) one or more substances selected from the group consisting of β-alanine and β-alanine precursors, or one or more pharmaceutically acceptable salts thereof; and (d) one or more substances selected from the group consisting of uridine and uridine precursors, or one or more pharmaceutically acceptable salts thereof, and / or one or more substances selected from the group consisting of inosine and inosine precursors, or one or more pharmaceutically acceptable salts thereof.

This invention belongs to the field of gene editing technology and discloses an inosine-enriched adenine base editor off-target detection method (Ino-seq) and its applications. The method of this invention utilizes endonuclease V to specifically cleave inosine-containing DNA, combined with the stabilization of a thermostable single-stranded DNA-binding protein and the high affinity enrichment of streptavidin-biotin, to achieve direct capture of ABE enzymatic products. This method can simultaneously detect sgRNA-dependent and independent off-target effects, with systematic comparisons showing F1 scores of 0.892–0.931. Targeted deep sequencing validation showed an overall accuracy of 95.3%. Ino-seq can also detect endogenous genomic inosine, observing a variation range of >1,000-fold in 10 cell lines. This invention provides a crucial safety assessment tool for the clinical translation of ABE technology, supporting comprehensive off-target analysis in preclinical and clinical studies.

This invention relates to the fields of molecular markers and animal genetic breeding technology, and particularly to a SNP marker that affects porcine inosine content and its application. Based on purebred American Landrace, purebred American Large White, and purebred American Duroc pigs, this invention studies and identifies 10 SNP molecular markers closely related to porcine inosine content. By optimizing the dominant alleles of these SNPs, the frequency of dominant alleles can be increased generation by generation, reducing inosine content, accelerating the progress of pig genetic improvement, and thus effectively improving the economic benefits of pig breeding.

Provided herein are eukaryotic cells that express an exogenously introduced inosine 5 '-monophosphate dehydrogenase (IMPDH) that is resistant to purine biosynthesis inhibitors, uses of the enzyme in the production of therapeutic drugs and in the treatment of diseases or conditions, as well as related pharmaceutical compositions and methods of preparation thereof.

The application discloses a hyperuricemia non-human primate model and a construction method thereof, and belongs to the technical field of experimental animals. The construction method comprises the following steps: using a non-human primate, i.e., a cynomolgus monkey, as a model animal, orally administering potassium oxonate and intravenously injecting myo-inositol, so that the blood uric acid content of the cynomolgus monkey is significantly increased within 0.5-8 hours, and the process can be inhibited by a uric acid-lowering drug allopurinol, and based on this, a hyperuricemia model of a non-human primate can be formed. Compared with a model constructed by using rodents, the hyperuricemia non-human primate model constructed by the application can better simulate the related symptoms and physiological processes of human hyperuricemia, and provides a preclinical effect evaluation tool for the research and development of nutrients and drugs in related fields.

The invention relates to the technical field of microbial engineering modification, and discloses a high-inosine-yield engineering strain, which is constructed by taking a high-inosine-yield mutant strain obtained by ARTP mutagenesis as an original strain and expressing a phosphoribose pyrophosphate synthase (prsA) gene. The high-yield inosine engineering strain is named as S1951, and is preserved in the China General Microbiological Culture Collection Center (CGMCC) on June 30, 2025, and the preservation number is CGMCC NO.35056. The invention further discloses a preparation method of the high-yield inosine engineering strain. The inosine mutant has the following technical effects that the inosine mutant is obtained through combination of ARTP mutagenesis and metabolic engineering modification, the inosine yield of the inosine mutant is remarkably improved, the inosine mutant has relatively stable hereditary performance, the preparation method is simple, and the preparation cost is relatively low. The invention further discloses a construction method and application of the high-inosine-yield engineering strain.

Endonuclease V Immunostaining Assay (EndoVIA) is provided herein as the first approach for quantifying and visualizing the landscape of Adenosine-to-Inosine (A-to-I) edited RNAs in situ. EndoVIA provides rapid quantification of overall inosine abundance and allows cell-to-cell comparison of A-to-I editing levels without the need for RNA sequencing. EndoVIA contributes valuable new insights into the dynamic interplay between A-to-I editing and subcellular localization that are undetectable with currently available approaches.

The present invention relates to antisense oligonucleotides (AONs) that can mediate RNA editing by binding to a target RNA nucleic acid molecule, preferably an RNA transcript molecule, in a cell and recruiting an endogenous deaminating enzyme in the cell to deaminate a target adenosine in the target RNA molecule to an inosine. The target RNA molecule is a transcript molecule form the SLC10A1 gene that encodes the Na+ / Taurocholate Co-transporting Polypeptide (NTCP). The RNA editing of the target adenosine will result in a loss- of-function of the NTCP protein, which will result in lowered uptake of bile acids from the portal circulation into the liver, thereby lowering the risk of suffering from disorders related to bile accumulation in the liver.

The invention discloses a composition for relieving wheat salt stress and application. The invention relates to an application of at least one of inosine, methylmalonic acid and adenosine in improvement of wheat salt stress resistance. The composition comprises salicylic acid, inosine, indoleacetic acid, methylmalonic acid and adenosine. The molar ratio of salicylic acid to inosine to indoleacetic acid to methylmalonic acid to adenosine is 1: 1: 10: 10: 1. Salicylic acid, inosine, indoleacetic acid, methylmalonic acid and adenosine are taken as a single substance or a composition of the salicylic acid, inosine, indoleacetic acid, methylmalonic acid and adenosine as an exogenous preparation for relieving salt stress of wheat, so that the salt stress resistance of the wheat can be improved, the fresh weight, dry weight and root indexes of the wheat can be improved, and the antioxidant enzyme activity under the salt stress of the wheat can be improved; the soil available phosphorus content and the soil enzyme activity are improved, and the wheat rhizosphere microbial structure is regulated and controlled.

The invention relates to a proton radiation brain injury tissue marker and application thereof, radiation brain injury differential metabolite markers comprise prostaglandin F2alpha, fructose-1, 6-diphosphate, dihydroxyacetone phosphate and inosine, and differential protein markers comprise fibroblast growth factor receptor 2 and calcium / calmodulin dependent protein kinase II. Differential metabolites and differential proteins are used as proton radiation brain damage biomarkers. According to the invention, the differential marker is used as a potential biomarker of radiation brain tissue injury, and demonstrative research is provided for multi-omics analysis of radiation brain injury and explanation of an action mechanism of radiation brain injury.

The invention discloses a preparation method of a 2 '-modified inosine monomer, and belongs to the technical field of synthesis of medical intermediates. The method comprises the following steps: by taking a compound I as a starting raw material, preparing a compound II under the action of adenosine deaminase, then reacting the compound II with DMTrCl to generate a compound III, purifying the compound III, and reacting with a phosphorus reagent to prepare a compound IV. According to the method, adenosine deaminase is used as a deamination catalytic enzyme, an adenosine derivative is converted into an inosine derivative, the reaction can be carried out in pure water, the reaction is fast, the condition is mild, almost no by-product is generated, after the reaction is finished, a solvent is used for crystal transformation, a compound II with the purity of 99% + can be obtained, DMTr is added to the compound II, a compound III is formed, the compound III does not need column chromatography, and the yield is high. And then further reacting with a phosphorus reagent to obtain the 2 '-modified inosine monomer derivative with the purity of 99% +.